

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

EO771

RRID:CVCL_GR23

Type: Cell Line

Proper Citation

CLS Cat# 305352, RRID:CVCL_GR23

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_GR23

Proper Citation: CLS Cat# 305352, RRID:CVCL_GR23

Description: Cell line EO771 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Defining Citation: [PMID:16312045](#), [PMID:24391448](#), [PMID:32699527](#), [PMID:33026171](#)

Comments: Miscellaneous: STR profile from personal communication of Rodriguez-Tarduchy Segovia, Gemma., Characteristics: Belongs to the luminal subtype B; ERalpha-, ERbeta+, PR+ and ErbB2+ (PubMed=32699527).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: EO771

Synonyms: Eo771, E0771, EO 771

Cross References: ATCC:CRL-3461, ChEMBL-Cells:ChEMBL4483168, ChEMBL-Targets:ChEMBL4483234, CLS:305352, PubChem_Cell_line:CVCL_GR23, Wikidata:Q54832331

ID: CVCL_GR23

Vendor: CLS

Catalog Number: 305352

Record Creation Time: 20260408T073026+0000

Record Last Update: 20260920T012618+0000

Ratings and Alerts

No rating or validation information has been found for EO771.

No alerts have been found for EO771.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 463 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Leu JS, et al. (2026) Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis. Cancer letters, 649, 218491.

Li W, et al. (2026) A microbiota-derived bile acid overcomes antibiotic-induced hyporesponsiveness to immune checkpoint therapy by enhancing CD8 + T cell antitumor immunity. bioRxiv : the preprint server for biology.

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. Cancer research, 86(6), 1414.

Tang XT, et al. (2026) Mapping the Tissue-of-Origins of Mesenchymal Stromal Cells in Injury Repair. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(3), e09533.

Zhou T, et al. (2026) Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(40), e21541.

Kiliti AJ, et al. (2026) An AIB1 isoform rewires glucocorticoid receptor signaling to promote TNBC progression. iScience, 29(2), 114768.

Niravath P, et al. (2026) A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1697.

Li G, et al. (2026) Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation. Cancer research, 86(10), 2327.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Chen F, et al. (2026) Hierarchical Targeting of TREM2+ Myeloid Cells via Acid-Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone-Metastatic TNBC. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(32), e17369.

McRae SW, et al. (2026) Linking tumor viability and immune infiltration with dual-nucleus MRI in preclinical models. *Npj imaging*, 4(1).

Young RG, et al. (2026) ACS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis. *Cancer research*, 86(14), 3502.

Hoyt-Miggelbrink AM, et al. (2026) Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(4), 782.

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. *Molecular cancer therapeutics*, 25(4), 610.

Yu J, et al. (2026) 6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation. *Neuron*, 114(14), 2532.

Tong Q, et al. (2026) Detachment-Induced FAK-STAT3-NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(29), e22837.

Alvarez-Eraso KLF, et al. (2026) Estradiol Reprograms Microglia to Create an Immune-Suppressed Niche Permissive to Breast Cancer Brain Metastasis. *bioRxiv : the preprint server for biology*.

Heard MA, et al. (2025) Genetic and pharmacological targeting of nicotinic acetylcholine receptor action blocks tumor progression in mouse models of breast cancer. *Journal of immunology* (Baltimore, Md. : 1950), 214(8), 2098.

Liang Z, et al. (2025) *Atractylodes macrocephala* Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis. *International journal of molecular sciences*, 26(20).

Beeghly GF, et al. (2025) Large adipocytes alter mode of lipid release and promote breast cancer malignancy. *bioRxiv : the preprint server for biology*.